Get all the latest news on coronavirus and more delivered daily to your inbox.  Sign up here.The experimental COVID-19 treatment remdesivir is showing early promise in the battle against the coronavirus outbreak, according to a small research study.The study, which was published in the New England Journal of Medicine, was supported by remdesivir developer Gilead Sciences. “These are patients who received treatment through the compassionate use program for remdesivir, which is for critically ill patients who are unable to take part in a clinical trial,” said Gilead CEO Daniel O’Day in an open letter released Friday. “The results, which cover 53 of the first patients to have been treated in the program, show that the majority demonstrated clinical improvement after taking remedesivir.”REMDESIVIR: WHAT TO KNOW ABOUT POTENTIAL CORONAVIRUS TREATMENTHowever, O’Day acknowledged the small scale of the research, which was not the result of a clinical trial.“We recognize the limitations of these compassionate use data from a purely investigational perspective, while knowing they are of the greatest significance for the patients whose symptoms improved,” he said, in the letter. “These early data from 53 patients have not been generated in a clinical trial and cover only a small portion of the

Continue To Full Article